Archive · 6 Oct 2026
Lupin Launches Triple-Combination COPD Inhaler in India
Lupin has launched a new inhaler in India for people with COPD.
COPD is a long-term lung disease.
The inhaler combines three medicines in one fixed dose.
It is meant for people with moderate to severe COPD and is used twice a day.
The launch came after approval from the Drug Controller General of India.
Lupin says the product adds an option for healthcare professionals treating suitable patients.
The company also says it strengthens its respiratory medicine portfolio.
The article reports that more than 5.5 crore people in India are affected by COPD.
Lupin announced the launch of Formoflo-G® MDI in India on 6 October 2026.
The inhaler combines Glycopyrronium Bromide, Formoterol Fumarate, and Fluticasone Propionate.
It is designed for long-term management of moderate to severe COPD and is taken twice daily.
The launch followed approval from the Drug Controller General of India.
Lupin said the launch expands its respiratory portfolio; the article reports COPD affects more than 5.5 crore people in India.
- Who
- Lupin Limited launched Formoflo-G® MDI.
- What
- A fixed-dose triple-combination inhaler for long-term management of moderate to severe COPD.
- When
- 6 October 2026.
- Where
- India.
- Why
- Lupin said the launch expands treatment options and addresses unmet needs for appropriate COPD patients.
- Product
- Formoflo-G® MDI, a fixed-dose triple-combination metered-dose inhaler
- Launch date
- 6 October 2026
- Company
- Lupin Limited
- Regulatory approval
- Drug Controller General of India (DCGI)
- Ingredients
- Glycopyrronium Bromide, Formoterol Fumarate, and Fluticasone Propionate
- Dosing
- Twice daily, available in a single strength
- Intended use
- Long-term management of moderate to severe COPD
- COPD prevalence stated
- More than 5.5 crore people in India